ICU study checks if blood filters zap Life-Saving antibiotics
NCT ID NCT07230041
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how a blood-filtering cartridge (HA 380) used with continuous kidney dialysis removes antibiotics in ICU patients with septic shock and kidney failure. Researchers will take blood samples before and after the filter at several time points to measure changes in antibiotic levels. The goal is to understand drug loss so doctors can better dose antibiotics in these critically ill patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- hemoadsorption cartridge (HA 380) and continuous renal replacement therapy
- What this could lead to
- If successful, this study could help doctors adjust antibiotic doses more accurately for ICU patients on blood purification, improving treatment effectiveness.
- What could go wrong
- This is a very small, early observational study with only 20 participants. It measures drug levels but does not test any new treatment or patient outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
ICU patients with a diagnosis of infection/sepsis/septic shock
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * stage 3 KDIGO consensus criteria, indication to CRRT * use of at least one of the following antibiotics meropenem, linezolid and daptomycin * \< 18 yo Exclusion Criteria: * \< 18 yo
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Niguarda Hospital
RECRUITINGMilan, Italia, 20162, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bedside eye scans may reveal hidden blood flow problems in septic shock
- Common Anti-Nausea drugs under scrutiny for kidney risk during chemo
- Heart attack delay may signal kidney risk after angioplasty
- ICU kidney injury: does the pattern predict lasting damage?
- Can two blood markers catch sepsis before it turns deadly?
- Can a kidney ultrasound scan warn of kidney damage after heart bypass surgery?